![share_log](https://pubimg.futunn.com/201912120187256955015721ae9.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Altimmune | 10-Q: Q2 2024 Earnings Report
Altimmune | 10-Q: Q2 2024 Earnings Report
Altimmune | 10-Q:2024財年二季報
牛牛AI助理已提取核心訊息
Altimmune, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company experienced a net loss of $24.64 million, a 53% increase from the $16.06 million loss reported in the same quarter of the previous year. Operating expenses rose by 49% to $26.75 million, driven by a 60% increase in research and development costs, particularly due to the ramp-up of the IMPACT Phase 2b trial for pemvidutide, their lead product candidate for obesity and metabolic dysfunction-associated steatohepatitis (MASH). General and administrative expenses also saw an 18% rise. Despite these increases, the company reported a slight 8% growth in other income, netting $2.105 million, primarily from interest income on cash equivalents and short-term investments. Altimmune's current cash, cash equivalents, restricted cash, and...Show More
Altimmune, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company experienced a net loss of $24.64 million, a 53% increase from the $16.06 million loss reported in the same quarter of the previous year. Operating expenses rose by 49% to $26.75 million, driven by a 60% increase in research and development costs, particularly due to the ramp-up of the IMPACT Phase 2b trial for pemvidutide, their lead product candidate for obesity and metabolic dysfunction-associated steatohepatitis (MASH). General and administrative expenses also saw an 18% rise. Despite these increases, the company reported a slight 8% growth in other income, netting $2.105 million, primarily from interest income on cash equivalents and short-term investments. Altimmune's current cash, cash equivalents, restricted cash, and short-term investments total $164.9 million, which they believe is sufficient to fund operations through 2025. On the business development front, Altimmune presented full results from their 48-week MOMENTUM Phase 2 obesity trial of pemvidutide, showing promising body composition changes. However, they announced the discontinuation of HepTcell development due to insufficient trial results. The company is also involved in ongoing litigation, including a class action and shareholder derivative complaints, which they intend to defend vigorously. Looking ahead, Altimmune is focused on advancing pemvidutide through clinical trials and has ceased further development of HepTcell.
臨床前生物製藥公司Altimmune報道了截至2024年6月30日的財務結果。公司淨損失2,464萬美元,比去年同期報告的1,606萬美元損失增長53%。營業費用增長了49%,達到2675萬美元,主要由於研發成本增加了60%,尤其是因爲IMPACt Phase 20億的pemvidutide領先產品候選藥物所致,用於肥胖和代謝功能障礙相關脂肪肝(MASH)的治療試驗。總務及行政費用也增長了18%。儘管出現了這些增長,公司報告了其他收入略微增長8%,共淨得210.5萬美元,主要來自於現金等價物及短期投資的利息收入。Altimmune現有的現金、現金等價物、限制性現金和短期投資總額爲16490萬美...展開全部
臨床前生物製藥公司Altimmune報道了截至2024年6月30日的財務結果。公司淨損失2,464萬美元,比去年同期報告的1,606萬美元損失增長53%。營業費用增長了49%,達到2675萬美元,主要由於研發成本增加了60%,尤其是因爲IMPACt Phase 20億的pemvidutide領先產品候選藥物所致,用於肥胖和代謝功能障礙相關脂肪肝(MASH)的治療試驗。總務及行政費用也增長了18%。儘管出現了這些增長,公司報告了其他收入略微增長8%,共淨得210.5萬美元,主要來自於現金等價物及短期投資的利息收入。Altimmune現有的現金、現金等價物、限制性現金和短期投資總額爲16490萬美元,他們認爲這足以支持運營至2025年。在業務發展方面,Altimmune發佈了pemvidutide 48周MOMENTUm phase 2肥胖試驗的完整結果,顯示出有前途的體成分變化。然而,他們宣佈由於試驗結果不足而取消HepTcell的開發。公司還涉及正在進行的訴訟,包括集體訴訟和股東衍生訴訟,他們打算堅決捍衛自己的權益。展望未來,Altimmune專注於推進pemvidutide進行臨床試驗,並停止了對HepTcell的進一步開發。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了